PolyPid (PYPD) grants director Dror-Darwish Nir 9,132 stock options at $4.46

Rhea-AI Filing Summary

PolyPid Ltd. director Dror-Darwish Nir received a grant of stock options covering 9,132 Ordinary Shares. The options have an exercise price of $4.46 per share, vest quarterly beginning July 15, 2026 until April 15, 2030, and expire on July 15, 2036. Following this award, he holds options for 9,132 shares, reported as direct ownership. The transaction is categorized as a grant or award acquisition rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dror-Darwish Nir

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	9,132	$4.46	$41K

Holdings After Transaction: Stock option (right to buy) — 9,132 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 9,132 options Exercise price: $4.46 per share Underlying shares: 9,132 Ordinary Shares +3 more

6 metrics

Options granted 9,132 options Stock option grant to director Dror-Darwish Nir

Exercise price $4.46 per share Exercise price of the granted stock options

Underlying shares 9,132 Ordinary Shares Ordinary Shares underlying the stock option grant

Option expiration July 15, 2036 Expiration date of the stock options

Vesting start date July 15, 2026 Quarterly vesting of options begins on this date

Vesting end date April 15, 2030 Quarterly vesting of options continues until this date

Key Terms

Stock option (right to buy), Ordinary Shares, vesting, exercise price

4 terms

Stock option (right to buy) financial

"Security titled "Stock option (right to buy)" granted to the director."

Ordinary Shares financial

"Each option is exercisable into Ordinary Shares of PolyPid Ltd."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vesting financial

"The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"The exercise price of the stock options is $4.46 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 04:03 PM Accepted by SEC EDGAR 07/17/2026 - 04:02 PM Learn about SEC filing dates

FAQ

What insider transaction did PolyPid (PYPD) director Dror-Darwish Nir report?

Dror-Darwish Nir reported a grant of stock options for 9,132 Ordinary Shares of PolyPid Ltd. The options are a compensation award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.

How many PolyPid (PYPD) options were granted to Dror-Darwish Nir and at what price?

He was granted 9,132 stock options with an exercise price of $4.46 per share. Each option is exercisable into one Ordinary Share, giving him the right to buy shares at that fixed price regardless of future market levels.

What is the vesting schedule for Dror-Darwish Nir’s PolyPid (PYPD) option grant?

The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030. This means portions of the 9,132 options become exercisable over time rather than all at once on the grant date.

When do Dror-Darwish Nir’s PolyPid (PYPD) stock options expire?

The stock options expire on July 15, 2036. After that date, any unexercised options will lapse, and he will no longer be able to buy Ordinary Shares under this particular grant at the $4.46 exercise price.

How many PolyPid (PYPD) options does Dror-Darwish Nir hold after this reported grant?

After this transaction, he holds 9,132 stock options directly. These options, once vested, allow him to purchase up to 9,132 Ordinary Shares at the fixed exercise price specified in the award.

Is Dror-Darwish Nir’s PolyPid (PYPD) option grant tied to a Rule 10b5-1 trading plan?

The award is categorized as a grant, award, or other acquisition and is not indicated as being made under a Rule 10b5-1 trading plan, distinguishing it from a pre-arranged trading program for open-market transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dror-Darwish Nir

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.46	07/15/2026		A		9,132		10/15/2026(1)	07/15/2036	Ordinary Shares	9,132	$4.46	9,132	D

Explanation of Responses:

1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

	/s/ Dror-Darwish Nir	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)